so are we expecting an anouncement?, page-33

Re Back of envelope calculations - GSK increased Relenza annual capacity to produce 190m packs beginning Nov 2009 if I remeber rightly.

At say $1-50 per pack (at 7% royalty and $24 per pack) - potential for 1 years production to yield $285m - and if working at full capacity since say Nov 2009 there should be close to 380m packs on hand (although I doubt they have been running at full capacity)

If they promted Relenza into the seasonal flu market (and not just concentrated on pandemic stockpiling) then perhaps they could move up to full production,

Regards
Kangaroo